Roivant Sciences, Inc.
156 articles about Roivant Sciences, Inc.
-
Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring
1/13/2020
Lokavant has entered into multi-year enterprise license agreement with Parexel
-
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
-
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
Roivant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Roivant Sciences announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent developments and future directions for the business at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
-
Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance
12/30/2019
Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma
-
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
-
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
11/1/2019
The agreement was formally signed yesterday. -
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences
10/31/2019
Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term
-
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
10/31/2019
Alliance will include Roivant's ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis
-
Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
9/6/2019
Parties have entered into a non-binding memorandum of understanding ("Memorandum"); a definitive agreement expected by the end of October 2019
-
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
9/6/2019
Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memorandum of understanding for the creation of a significant multi-national Sumitomo Dainippon-Roivant Alliance (“Alliance”) that will include Roivant’s ownership interests in Urovant Sciences and four additional biopharmaceutical “Vant” companies.
-
Roivant Provides Corporate Updates in Advance of Second Annual Pipeline Day
6/5/2019
Roivant Sciences today announced a series of corporate updates across the Roivant family of companies in advance of its second annual Pipeline Day tomorrow afternoon in New York City.
-
Roivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
5/14/2019
Second annual Roivant Pipeline Day on June 6th to feature additional clinical data from across Roivant family of companies
-
Medigene AG: Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
4/4/2019
Cytovant licenses East Asian rights for a research-stage T cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of patients across East Asia
-
Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
4/4/2019
Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of patients across East Asia-
-
Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.
-
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
3/19/2019
Vibegron met both co-primary endpoints and all seven key secondary endpoints
-
Axovant Sciences, one of Vivek Ramaswamy’s biotech companies under the Roivant Sciences’ umbrella, is forming a company called Arvelle Therapeutics. Arvelle is a strategic transition of Axovant’s legacy small molecule team.Biopharmaceuticals
-
Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress
1/31/2019
Altavant Sciences will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute 13th Annual World Congress on Pulmonary Vascular Disease, taking place in Barcelona, Spain from January 30 to February 3, 2019.